

# **Resource Consumption and Asthma Severity**

David U. Himmelberger

Health Outcomes Group, Palo Alto, CA

ISOQoL, Amsterdam, 6 November 2001

# Study Objective

- Evaluate the relationship between:
  - asthma severity (GINA)
  - and
  - resource consumption

# Study Methods

- **National survey of asthmatics**
- **Consecutive patients**
- **Physical evaluation of asthmatic status**
- **Patient self-report of resource consumption**
  - **limitation of activities – past 14 days**
  - **medication use and MD visits – past 6 months**
  - **hospitalization and lost work – past year**

# GINA Classification of Asthma Severity

- Intermittent — symptoms  $< 1$  time a week
- Mild Persistent — sym  $> 1$  time a week and  
sym  $< 1$  time a day
- Moderate Persistent — symptoms daily
- Severe Persistent — symptoms continuously

# **GINA Classification Using 7 Variables**

- **Daytime Symptoms**
- **Nocturnal Symptoms**
- **Attacks**
- **Use of beta-agonists**
- **Physical Activity**
- **FEV1**
- **PEF Variability**

# Distribution of Patients in Spain



**Total: 300 pts**

# Distribution of Patients in Italy



North	125 pts
Center	225 pts
South	150 pts
Total:	500 pts

# Demographics

	Italy	Spain
• Age	38.0	38.0 yrs
• Gender (male %)	42.8	28.3 %
• Married / Living together	59.8	62.3 %
• Education (primary or less)	12.4	50.0 %
• Employed	66.4	49.7 %



# Asthma Related Conditions

	Italy	Spain
• Rhinitis	56.8	51.0 %
• Sinusitis	21.2	13.7 %
• Atopic Dermatitis	3.8	6.0 %
• Chronic Urticaria	2.4	3.7 %
• Nasal Polyps	13.0	8.0 %
• Family History of Above	40.2	34.7 %


## **GINA Classification Asthma Severity – Past 14 Days**

	<b>Italy</b>	<b>Spain</b>
• <b>Intermittent</b>	<b>34.8</b>	<b>43.7 %</b>
• <b>Mild Persistent</b>	<b>26.8</b>	<b>28.3 %</b>
• <b>Moderate Persistent</b>	<b>30.6</b>	<b>23.0 %</b>
• <b>Severe Persistent</b>	<b>7.8</b>	<b>3.7 %</b>
Not Reported	<b>0.0</b>	<b>1.3 %</b>


## **GINA Classification Asthma Severity – Past Year**

	<b>Italy</b>	<b>Spain</b>
• Intermittent	27.2	29.0 %
• Mild Persistent	29.8	43.0 %
• Moderate Persistent	37.6	22.7 %
• Severe Persistent	5.4	3.0 %
Not Reported	0.0	2.3 %

# Morning Peak Flow - Italy




# Evening Peak Flow - Italy




# Resource Consumption

- **Past 14 days**
  - daytime symptoms
  - nocturnal symptoms
  - symptom free days
  - asthma medication use
  - limitation of activities
  - effects of attacks
- **Past year**
  - days missed from paid work
  - days missed from unpaid work
  - effectiveness at paid work
  - visits to emergency room
  - hospitalization
- **Past 6 months**
  - physician visits
  - use of asthma medications
  - oral steroid use

# Days Limited by Asthma - Spain



# Days Limited by Asthma - Italy






# Effect of Asthma for Patients with Intermittent vs Severe Asthma


	Italy	Spain
• Nights Awake	0.2 / 7.2	0.5 / 3.4
• Days with Symptoms	1.1 / 9.3	1.5 / 8.4
• Days Limited	0.2 / 8.2	0.3 / 5.2

(During the past 14 days)

# Lost Days of Paid Work - Italy




# Lost Days of Unpaid Work - Italy




# Effectiveness at Paid Work – Italy

(during past 14 days)



# Effects of Asthma Attacks – Italy

(during past 14 days)




# Physician Visits

## Intermittent vs Severe Asthma


	Italy	Spain
• Non specialists	1.9 / 7.9	1.8 / 6.2
• Pulmonologists	1.2 / 2.5	0.4 / 2.0
• Allergologist	1.4 / 2.3	0.3 / 2.0

(During the past 6 months)

# Consumption of All Inhaled Medications – Spain




# Consumption of All Inhaled Medications – Italy





# Consumption of All Oral Medications – Italy




# Non-planned Visits and Procedures

## Intermittent vs Severe Asthma


	Italy	Spain
• Hospitalization Rate	0.05 / 1.12	0.03 / 0.22
• Days Hospitalized	0.4 / 10.2	4.3 / 3.0
• Visits to Emergency	0.1 / 1.7	1.1 / 2.7
• Courses of Oral Steroids	0.4 / 2.2	0.3 / 1.7

(During the past year)

# Average Cost per Patient per Year – Spain



# Distribution of Cost – Spain



# Limitations

- Possible selection bias in participants
- Self reported data
- Small representation of severe asthma
- Better measures of pulmonary function
- Better economic data

# Summary

- ❖ More major medical problems
- ❖ Peak flow 10% lower than predicted
- ❖ Use of inhalers 2.5 times higher
- ❖ Days with symptoms 3 times higher
- ❖ Nights awake 3 times higher
- ❖ Days limited 3 – 5 times higher
- ❖ Asthma attacks 3 times higher
- ❖ More frequent hospitalization
- ❖ Longer length of stay

# Conclusions

- **Resource consumption increases as asthma severity increases**
- **Relative cost of medications is higher for patients with less severe asthma**
- **Peak flow was not related to asthma severity**
- **Resource consumption was 2 – 3 times higher in natural units**
- **Resource consumption was 6 times higher in monetary units (in Spain)**